LNCB74 is a B7-H4-targeting antibody-drug conjugate being developed for multiple cancers in partnership with LigaChem BiosciencesBELTSVILLE, Md., Dec. 10, 2024…
Based on more than six months of additional monitoring, data show continued improvement in overall survival (OS) in intent-to-treat (ITT)…
Award is being presented during Advanced Therapies Week 2025 in DallasMarlborough, Massachusetts--(Newsfile Corp. - December 10, 2024) - Phio Pharmaceuticals…
54% of patients experience more than 2.5 years of durable hematocrit (Hct) control (<45%), decreased phlebotomy use, long-term tolerability, and…
PLANO, Texas, Dec. 9, 2024 /PRNewswire/ -- ESPN Events along with the Orlando Sports Foundation (OSF) announced that Jacksonville State…
DELRAY BEACH, Fla. , Dec. 9, 2024 /PRNewswire/ -- The global AI in medical diagnostics market is likely to grow from…
The online custom card company pledges to donate $5 for every card purchased to support St. Jude with a specially…
Clinician-trained AI analyzes electronic records to match ideal patients with studies in seconds rather than hours, optimizing research and reducing…
Findings to be Presented at the San Antonio Breast Cancer Symposium NEW YORK, Dec. 9, 2024 /PRNewswire/ -- COTA Inc., a…
Adult patients with breast cancer are a prespecified subgroup of the recently conducted OnTarget trial evaluating crofelemer for prophylaxis of…